The primary efficacy endpoint was the change in C-peptide.

Treatment with Diamy not reach a statistically significant effect for each of the secondary endpoint. ‘I’m obviously of the study of the study and surprised that we do not see, given a greater total effect earlier studies,’Dr. Johnny Ludvigsson, principal investigator and at the at the Link-ping University? other therapeutic areas, deny this treatment based on the fact that this study is based not reach statistical significance. We need to learn from other therapeutic areas, such as allergies and cancer that progressed through the combination of different treatments, each of which may have a limited impact be be It is also possible that the treatment is effective in the prevention of type 1 diabetes.

‘courtesy of you, the entire Kaiser Daily Health Policy Report view, looking at the archives, or sign up for email delivery at Kaiser Daily Health Policy Report strongly supports kaiser network. A free service of The Henry J. Releases. Kaiser Family Foundation. 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved. Johnny Ludvigsson presents the detailed results of Diamyd Medical European Phase III study of the antigen-based diabetes therapy Diamy.In subjects with mild gallstone pancreatitis as a rule stay in the hospital for several days to decay await symptoms undergo before one operation to address the condition. A new study of researchers at Los Angeles Biomedical Research Institute show patient can not wait so long on surgery and was earlier sooner.